Comparative Pharmacology
Head-to-head clinical analysis: TIGAN versus VONTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIGAN versus VONTROL.
TIGAN vs VONTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TIGAN (trimethobenzamide) acts on the chemoreceptor trigger zone (CTZ) to inhibit emetic stimuli, primarily through antagonism of dopamine D2 receptors, though its exact mechanism is not fully elucidated.
VONTROL (trimethobenzamide) acts centrally to inhibit the chemoreceptor trigger zone (CTZ) in the medulla oblongata, thereby suppressing nausea and vomiting. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and serotonin 5-HT3 receptors.
Adults: 200 mg IM or 100 mg PO or 200 mg PR every 6–8 hours as needed.
10 mg orally twice daily; maximum 20 mg/day.
None Documented
None Documented
12-15 hours; may be prolonged in hepatic impairment.
12 hours; prolonged in renal impairment (up to 24 hours in ESRD)
Renal (30-50% as unchanged drug and metabolites), biliary/fecal (minor).
Renal: 60% unchanged; fecal: 30% (biliary); hepatic metabolism: 10%
Category C
Category C
Antiemetic
Antiemetic